Revelation Biosciences, Inc.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2019-07-31 | Patrick J. Toomey · R-PA | Senate | Sold | $15,001 - $50,000 |
| 2018-07-27 | Patrick J. Toomey · R-PA | Senate | Sold | $15,001 - $50,000 |
| 2018-06-25 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2018-06-06 | Patrick J. Toomey · R-PA | Senate | Sold | $15,001 - $50,000 |
| 2018-04-30 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2018-03-22 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2018-02-08 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2018-01-30 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2018-01-08 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2017-12-07 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
Show the other 3
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2017-11-30 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2017-11-17 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
| 2017-11-15 | Patrick J. Toomey · R-PA | Senate | Sold | $1,001 - $15,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.